Literature DB >> 20599289

Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-tolerant human lung cancer cells.

Yidan Lin1, Ziqiang Wang, Lunxu Liu, Longqi Chen.   

Abstract

Cisplatin [cis-diaminodichloroplatinum (II) (CDDP)] is the cornerstone of lung cancer chemotherapy. However, its efficacy is limited due to the development of drug resistance in cancer cells. This study was designed to uncover the mechanisms under CDDP resistance in lung cancer cells involving endoplasmic reticulum (ER) stress tolerance-induced and GRP78-dependant Akt activation. In this study we established ER stress-tolerant (ERST) human lung cancer lines H460et and A549et. We found that the ERST Lung cancer cells are resistant to CDDP treatment. We further showed that, compared to the parental cell lines, H460et and A549et show significantly increased GRP78 and phospho(p)-Akt levels. And phosphorylation of Akt, which can be regulated by GRP78, is essential to the ERST-associated CDDP resistance. Our findings identify a new mechanism of regulating Akt activity and a new mechanism through which CDDP resistance is formed in lung cancer cells.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20599289     DOI: 10.1016/j.lungcan.2010.06.004

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  28 in total

1.  The critical role of GRP78 in physiologic and pathologic stress.

Authors:  Kyle T Pfaffenbach; Amy S Lee
Journal:  Curr Opin Cell Biol       Date:  2010-10-21       Impact factor: 8.382

2.  Cell intrinsic role of COX-2 in pancreatic cancer development.

Authors:  Reginald Hill; Yunfeng Li; Linh M Tran; Sarah Dry; Joseph Hargan Calvopina; Alejandro Garcia; Christine Kim; Ying Wang; Timothy R Donahue; Harvey R Herschman; Hong Wu
Journal:  Mol Cancer Ther       Date:  2012-07-10       Impact factor: 6.261

3.  ER stress modulates cellular metabolism.

Authors:  Xiaoli Wang; Colins O Eno; Brian J Altman; Yanglong Zhu; Guoping Zhao; Kristen E Olberding; Jeffrey C Rathmell; Chi Li
Journal:  Biochem J       Date:  2011-04-01       Impact factor: 3.857

4.  Role of endoplasmic reticulum stress on cisplatin resistance in ovarian carcinoma.

Authors:  Jing Tian; Rong Liu; Quanxin Qu
Journal:  Oncol Lett       Date:  2017-01-10       Impact factor: 2.967

5.  GIV/Girdin promotes cell survival during endoplasmic reticulum stress.

Authors:  Peter Nguyen; Rosanna Calderon; Yoanna Rodriguez-Ledezma; Kelly Araujo; Deepali Bhandari
Journal:  Mol Cell Biochem       Date:  2018-08-25       Impact factor: 3.396

6.  AKT inhibition mitigates GRP78 (glucose-regulated protein) expression and contribution to chemoresistance in endometrial cancers.

Authors:  Michael J Gray; Paulette Mhawech-Fauceglia; Eunjeong Yoo; Wangrong Yang; Eijean Wu; Amy S Lee; Yvonne G Lin
Journal:  Int J Cancer       Date:  2013-02-08       Impact factor: 7.396

7.  HSPA5 negatively regulates lysosomal activity through ubiquitination of MUL1 in head and neck cancer.

Authors:  Sun-Yong Kim; Hyo Jeong Kim; Haeng-Jun Kim; Dae Ho Kim; Jae Ho Han; Hyung Kwon Byeon; Keunho Lee; Chul-Ho Kim
Journal:  Autophagy       Date:  2018-02-21       Impact factor: 16.016

Review 8.  A new strategy of promoting cisplatin chemotherapeutic efficiency by targeting endoplasmic reticulum stress.

Authors:  Ye Xu; Chunyan Wang; Zhixin Li
Journal:  Mol Clin Oncol       Date:  2013-10-18

9.  Regulation of AKT phosphorylation at Ser473 and Thr308 by endoplasmic reticulum stress modulates substrate specificity in a severity dependent manner.

Authors:  Hong Wa Yung; D Stephen Charnock-Jones; Graham J Burton
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240

10.  Identification of cisplatin-binding proteins using agarose conjugates of platinum compounds.

Authors:  Takatoshi Karasawa; Martha Sibrian-Vazquez; Robert M Strongin; Peter S Steyger
Journal:  PLoS One       Date:  2013-06-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.